The lamotrigine titration schedule exists for one reason: rash risk. Lamotrigine must be started low and increased slowly — typically 25 mg daily for two weeks, 50 mg daily for two weeks, then doubled by 50 mg each week to 200 mg daily by week six — because the risk of serious cutaneous adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, is highest when the drug is initiated too fast, particularly in the first two months.
This article is the complete working guide to lamotrigine titration for MRCPsych, USMLE and RANZCP candidates: the standard adult schedule week by week, how valproate and enzyme inducers rewrite it, how to separate a benign maculopapular rash from a dangerous one, and the rule that overrides everything — a non-trivial rash means stop immediately and never rechallenge. Learn this as a system and the exam questions answer themselves.
The standard lamotrigine titration schedule (adults)
The schedule below is the licensed adult initiation for bipolar disorder maintenance (the commonest psychiatric indication). It looks absurdly slow next to an SSRI — until you see the rash incidence data. Note the shape of it: two fixed starter weeks, then weekly doubling, then a plateau at the target dose.
| Phase | Standard schedule | With valproate (levels ~×2) | With carbamazepine, phenytoin or other inducers |
|---|---|---|---|
| Weeks 1–2 | 25 mg once daily | 12.5 mg once daily (halve everything) | 25 mg once daily |
| Weeks 3–4 | 50 mg once daily | 25 mg once daily | 100 mg daily — double the usual rate from here |
| Week 5 | 100 mg daily | 50 mg daily | 200 mg daily |
| Week 6 | 150 mg daily | 75 mg daily | 300 mg daily |
| Week 7+ | 200 mg daily (target maintenance 100–200 mg) | 100 mg daily (often the ceiling) | 300–400 mg daily |
Three practical notes on the table. First, doses above 100 mg/day are usually split twice daily to limit peak-level side effects (dizziness, diplopia, ataxia) — titration counts total daily dose. Second, valproate inhibits lamotrigine glucuronidation (UGT1A4), roughly doubling exposure: halve every step, and watch that the patient doesn't drift into "double dose, half schedule" territory, which is the commonest prescribing error on the ward. Third, enzyme-inducing drugs accelerate clearance, so the dose must go up faster to reach the same brain concentration — hence the doubled rate and the higher 300–400 mg maintenance range.
Why lamotrigine must be started so slowly
Lamotrigine's rash risk is concentration- and initiation-rate-dependent. The mechanism isn't fully settled, but two features explain the caution: the rash is idiosyncratic and immune-mediated (HLA-linked, with HLA-B*15:02 implicated in serious reactions in patients of Southeast Asian ancestry — screening is advised in at-risk populations per the product label), and the danger window is the first exposure, not steady-state dosing.
The numbers to carry into the exam:
- Any rash: roughly 10% of adults on lamotrigine develop a benign maculopapular rash — usually self-limiting, appearing in the first 2–4 weeks.
- Serious rash (SJS/TEN): on the order of 0.1% of adults and up to roughly 0.3–0.8% in children under 16 not co-prescribed valproate — a small number, a catastrophic outcome.
- Timing: the large majority of serious reactions — commonly cited as around 90% — occur within the first 8 weeks of therapy, and most in the first 2–4 weeks.
- Valproate: doubles lamotrigine exposure and is the sharpest modifiable risk factor; children clear lamotrigine faster, which is part of why paediatric initiation uses even smaller increments.
That first-exposure concentration dependence is why restarting after a break is a full re-initiation, not a pickup: clearance changes far less than immune priming does.
Exam trap
Two answers are almost never right. (1) A rash on lamotrigine: you stop the drug immediately and do not rechallenge — a non-trivial rash ends lamotrigine permanently; re-prescribing after Stevens-Johnson syndrome is indefensible at any dose. (2) A patient on valproate needing lamotrigine: the dose is halved (valproate doubles lamotrigine levels), not kept at standard or adjusted weekly. In a viva, say "stop, never restart" before you are asked.
Benign rash versus a dangerous rash: the red flags
Not every rash on lamotrigine is Stevens-Johnson syndrome — but you cannot wait for certainty. The practical question at the bedside is: is anything suggesting SCAR? Escalate and stop the drug on any of the following:
- Mucosal involvement — any erosion or blistering of lips, mouth, conjunctivae or genitals (the single most discriminating sign).
- Systemic features — fever, facial oedema, lymphadenopathy, headache, myalgia.
- Skin morphology — painful, atypical, targetoid or purpuric lesions, skin detachment, or a rash spreading rapidly over hours.
- Context — very early in titration, higher dose too soon, or valproate on board.
A simple non-itchy maculopapular rash confined to the trunk, with no mucosa, no fever, and a well child or adult, is more likely the common benign rash — but it still triggers a same-day prescriber review and usually a hold, with the diagnosis confirmed before any restart is even discussed. Severe cutaneous adverse reactions also include DRESS (drug reaction with eosinophilia and systemic symptoms) and AGEP, so watch bloods as well as skin when the picture is atypical.
What to do when a rash appears — and the missed-dose rule
The management algorithm is short because hesitation is the enemy:
- Stop lamotrigine immediately at any concerning rash and arrange urgent assessment. For confirmed or suspected SJS/TEN or DRESS: emergency admission, and do not rechallenge under any circumstances — this is written into MHRA drug-safety guidance and every major formulary.
- Document the reaction clearly (morphology, sites, mucosa, timing relative to dose steps) — it follows the patient for life and must appear in the allergy section of every future summary.
- Restart only for a benign, resolved rash and only after specialist discussion; if it ever happens, re-initiation starts again at 25 mg with an even slower escalation. "Non-trivial rash" means the door stays shut.
- Missed doses reset the clock. If more than five half-lives have elapsed — roughly five days off for most adults on standard doses, longer when valproate is co-prescribed — the schedule restarts from 25 mg. Coming back to 200 mg after a fortnight's gap is a de facto re-initiation and, by rash logic, a re-exposure to a first-dose risk.
That last rule is the one trainees forget. The titration schedule and the restart rule are the same safety mechanism wearing two hats: total exposure from a standing start is what the immune system reacts to. It is also why discharge summaries must state the exact dose and the date it was started — "continue lamotrigine 100 mg" with no start date hides a potential re-initiation hazard from the GP picking it up.
Frequently asked questions
What is the standard lamotrigine titration schedule?
Adults: 25 mg daily for weeks 1–2, 50 mg daily for weeks 3–4, then increase by 50 mg daily each week — 100 mg in week 5, 150 mg in week 6 — reaching a target maintenance dose of 100–200 mg daily by week 7 (split twice daily above 100 mg). With valproate, halve every step; with enzyme inducers such as carbamazepine or phenytoin, double the rate after week 2, typically targeting 300–400 mg daily.
Why does lamotrigine cause rash and how do I reduce the risk?
The rash is an idiosyncratic, immune-mediated reaction that is initiation-rate and concentration dependent — slow titration directly lowers it. Roughly 10% of adults get a benign rash, and serious reactions (SJS/TEN) occur in about 0.1% of adults and up to ~0.3–0.8% of children, with around 90% of serious cases in the first 8 weeks. Risk is highest with fast starts and with valproate, which doubles lamotrigine levels — hence the halved schedule.
What should you do if a patient develops a rash on lamotrigine?
Stop the drug immediately and arrange urgent same-day review; escalate to emergency care for any mucosal involvement, blistering, fever, facial oedema or rapid spread. Suspected Stevens-Johnson syndrome or toxic epidermal necrolysis is an admission. Never rechallenge after a serious cutaneous adverse reaction — document it as a lifelong allergy. Even a mild benign rash warrants a hold until the prescriber confirms the plan.
How long can a patient miss lamotrigine doses before restarting the titration?
More than five half-lives off the drug means restarting from 25 mg — practically five days or more for most adults, and longer when valproate co-prescription slows clearance. In children, clearance is faster so the window is shorter. Because rash risk attaches to re-initiation, a long gap without a proper restart schedule is a safety hazard, not a convenience.
Key takeaways
- Standard adult schedule: 25 mg × 2 weeks → 50 mg × 2 weeks → +50 mg weekly to 200 mg by week 7; target maintenance 100–200 mg daily.
- Valproate doubles lamotrigine levels — halve every step; enzyme inducers force the dose to go up twice as fast (300–400 mg target).
- Rash risk is front-loaded: benign rash ~10% of adults, serious rash ~0.1% of adults and higher in children, ~90% within the first 8 weeks.
- Mucosal involvement, fever, facial oedema or rapid spread = SCAR until proven otherwise: stop, urgent review, admit if suspected SJS/TEN.
- After a serious rash: stop permanently, never rechallenge, document as a lifelong allergy.
- Missing more than five half-lives (≈5 days) means the whole schedule restarts at 25 mg.
The lamotrigine titration schedule is one of psychiatry's few "never improvise" protocols: slow in, constant vigilance for the first eight weeks, and a zero-tolerance response to rash. Drill the dose steps until they're automatic — our spaced-repetition flashcards cover titration schedules exactly this way, and you can check yourself under timed conditions with a mock exam on MRCPsych pharmacology.
Cover image: “Lamotrigine Titration and Rash Risk (cover)” by Preppsy Editorial Team (Original artwork) via Preppsy.
